secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTELLIGENT BIO SOLUTIONS INC. (INBS)
CIK:        0001725430
Form:       8-K
Filed at:   2026-11-10T21:30:35+00:00
Accession:  0001493152-26-050982
Event type: earnings
Sentiment:  positive
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Intelligent Bio Q1 FY27 revenue $1.39M, up 25% YoY, record; gross margin 54.5%; FDA 510(k) filed Sept 9
--------------------------------------------------------------------------------

- Total revenue $1,391,835, up 25% year-over-year and 21% sequentially; third straight quarter above $1M and a company record, topping $1,145,802 in Q4 fiscal 2026.
- Cartridge sales $845,583 (+32% YoY, +35% sequentially), 61% of revenue; other sales $281,253 (+52% YoY), 20% of revenue.
- Gross profit $758,004, up 46% YoY; gross margin 54.5% vs 46.6% a year ago, roughly 790 bps better on manufacturing efficiencies and cartridge mix.
- Cash and equivalents $5.93M at Sept 30, 2026 vs $3.99M at June 30; 516 active customer accounts (27 added in the quarter) and 1,978 readers installed.
- FDA 510(k) submitted Sept 9, 2026 for the Intelligent Fingerprinting Drug Screening System (codeine); study showed accuracy >98%, sensitivity >94%, specificity 100% at three US sites.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1725430/000149315226050982/0001493152-26-050982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1725430/000149315226050982/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-050982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer